| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
HTLV bZIP factor (HBZ) is consistently expressed in HTLV-1 infected cells and ATL cells. Therefore, HBZ is a potential therapeutic target for immunotherapy of HTLV-1 related diseases and adult T cell leukemia (ATL). In this study, we generated and characterized HBZ-specific CTLs using HBZ-expressing recombinant vaccine virus (rVV-HBZ). HBZ-specific CTLs were induced in rVV-HBZ immunized mice (C57BL/6) and produced effector cytokines (IFN-γ and TNF-α) by HBZ peptide stimulation. HBZ specific T cell response was also observed in rVV-HBZ-immunized Rhesus macaque. These HBZ-specific CTLs were produced effector cytokines by HBZ157-176 peptide stimulation. Furthermore we generated human HBZ specific CTLs from HLA-A2 and HLA-A24 positive healthy donor using HBZ157-176 peptide. The HBZ specific CTLs produce effector cytokines when stimulated with HBZ157-176 peptide-pulsed BLCL. This study suggests that HBZ specific CTLs could be useful for ATL treatment.
|
